突变型SETBP1激活Myc程序转录加速CSF3R驱动的骨髓增殖性肿瘤
本研究建立SETBP1突变白血病模型,探讨SETBP1在慢性中性粒细胞白血病(CNL)中的作用。SETBP1突变在体外促进CSF3R突变造血祖细胞自我更新并阻止终末分化,在体内加速白血病进展导致肝脾肿大和粒细胞增多。转录组和表观基因组分析发现SETBP1上调Myc及其靶基因,该上调可被LSD1抑制剂逆转。
要点
- SETBP1突变在体外促进CSF3R突变造血祖细胞自我更新并阻止终末分化。
- SETBP1突变在体内加速白血病进展,导致快速发生肝脾肿大和粒细胞增多。
- SETBP1通过上调Myc及其靶基因增强祖细胞相关程序,可被LSD1抑制剂逆转。
核心结论
- SETBP1突变与突变型CSF3R共表达时通过上调Myc相关基因表达程序促进侵袭性造血细胞扩增。
研究设计与样本
- 本研究建立SETBP1突变白血病模型以理解SETBP1在CNL中的作用。
主要发现
- SETBP1突变在体外促进CSF3R突变造血祖细胞自我更新并阻止细胞终末分化。
- SETBP1突变在体内加速白血病进展,导致快速发生肝脾肿大和粒细胞增多。
- 转录组和表观基因组分析发现SETBP1增强祖细胞相关程序,最强上调Myc和Myc靶基因。
- Myc的上调可被LSD1抑制剂逆转。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colony stimulating factor 3 receptor (CSF3R) mutations lead to JAK pathway activation and are the molecular hallmark of chronic neutrophilic leukemia (CNL). Approximately half of patients with CNL also have mutations in SET binding protein 1 (SETBP1). In this study, we developed models of SETBP1-mutated leukemia to understand the role that SETBP1 plays in CNL. SETBP1 mutations promote self-renewal of CSF3R-mutated hematopoietic progenitors in vitro and prevent cells from undergoing terminal differentiation. In vivo, SETBP1 mutations accelerate leukemia progression, leading to the rapid development of hepatosplenomegaly and granulocytosis. Through transcriptomic and epigenomic profiling, we found that SETBP1 enhances progenitor-associated programs, most strongly upregulating Myc and Myc target genes. This upregulation of Myc can be reversed by LSD1 inhibitors. In summary, we found that SETBP1 mutations promote aggressive hematopoietic cell expansion when expressed with mutated CSF3R through the upregulation of Myc-associated gene expression programs.
引用
- Carratt SA, Kong GL, Curtiss BM, et al. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms. Blood. 2022. PMID: 35482940. doi:10.1182/blood.2021014777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。